Qualigen (NASDAQ:QLGN) inks an agreement with
the University of Louisville (UofL) that will facilitate the
development of candidate AS1411 to the potential treatment of COVID-19.
It has owned exclusive rights to AS1411 for all
uses since 2018 but the new deal provides a license under UofL’s pending
U.S. patent for its use in preventing or treating COVID-19.
AS1411 is a DNA aptamer (short single-stranded DNA that can selectively bind to a target).
https://seekingalpha.com/news/3581893-qualigen-closes-license-deal-for-as1411-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.